Allopathic clinicians should treat local health practitioners as equal partners in cross-cultural clinical practice and express respect for traditional therapies.
AMA J Ethics. 2016;18(7):691-697. doi:
10.1001/journalofethics.2016.18.7.ecas4-1607.
Defining typical appearance as a goal of health service provision is harmful and unnecessary for traits that are stigmatized but neither harmful nor distressing.
AMA J Ethics. 2021;23(7):E569-575. doi:
10.1001/amajethics.2021.569.
Charles E. Binkley, MD, Michael S. Politz, MA, and Brian P. Green, PhD
If the safe-and-effective standard for judging devices’ potential as therapy or enhancement is inadequate, one might wonder whether BCI regulation should be overseen by the FDA.
AMA J Ethics. 2021;23(9):E745-749. doi:
10.1001/amajethics.2021.745.
Dr Charles Binkley joins Ethics Talk to discuss his article, coauthored with Michael Politz and Dr Brian Green: "Who, If Not the FDA, Should Regulate Implantable Brain-Computer Interface Devices?"
Vaccination rates among adolescents and young adults, for whom the risk of infection is greatest, remain lower than was true for other vaccines in their first years. And vaccination rates among males is extremely low.
AMA J Ethics. 2015;17(9):854-857. doi:
10.1001/journalofethics.2015.17.9.msoc1-1509.
Introduction of an intervention that reduces the perceived risk of a given behavior may cause a person to increase risky behavior—this is called “risk compensation.”
Guidelines exist for delivery-room treatment for newborns at the margins of viability, and when the rules and limits are reached, parental values are important.
Guidelines exist for delivery-room treatment for newborns at the margins of viability, and when the rules and limits are reached, parental values are important.